Drug Profile

Tegavivint - Apollomics/Iterion Therapeutics

Alternative Names: APL-121; BC-2059; Tegatrabetan - Iterion therapeutics

Latest Information Update: 12 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BetaCat Pharmaceuticals
Developer Apollomics; Iterion Therapeutics; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center
Class Anthracenes; Antineoplastics; Hydroxylamines; Nitroso compounds; Piperidines; Small molecules; Sulfonamides
Mechanism of Action Beta catenin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Osteosarcoma; Fibroma
New Molecular Entity Yes

Phase II Fibroma
Phase I/II Liver cancer; Solid tumours
Phase I B-cell lymphoma; Osteosarcoma
Preclinical Lymphoma
No development reported Acute myeloid leukaemia; Multiple myeloma; Non-small cell lung cancer

10 Feb 2026 Tegavivint - Apollomics/Iterion Therapeutics receives Orphan Drug status for Osteosarcoma in USA
10 Feb 2026 Tegavivint receives Pediatric Rare Disease Designation for Osteosarcoma in USA
28 Jan 2026 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in China

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com